Scalper1 News
AbbVie (ABBV) late Wednesday said that its board of directors recommendation that shareholders reject a planned $55 billion buy of Shire Pharmaceuticals. The board citing new Treasury rules issued Sept. 22 making tax inversion deals less attractive. Abbvie said in a statement: “The breadth and scope of the changes, including the unexpected nature of the exercise of administrative authority to impact longstanding tax principles, and to target Scalper1 News
Scalper1 News